Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. NOXXON Pharma NV is a biotechnology company based in the Netherlands that focuses on cancer treatments. Noxxon Pharma NV (EU:ALNOX) Historical Stock Chart. Connexion membre Connexion client Nouveau sur Boursorama ? Click here for more on how to use these ratings. NOXXON Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment. Before it's here, it's on the Bloomberg Terminal. and Personal Securities Trading Policy in carrying out his responsibilities. Access our live streaming chart for the Noxxon Pharma AG stock, free of charge. NOXXON Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial, Viewpoint Molecular Targeting(TM) Appoints Frank Morich, M.D., Ph.D. to its Board of Directors, NOXXON Announces €1.2M Equity Raise Through Conversion of Warrants by Kreos Capital and Other Historical Investors, Noxxon Pharma N.V. Reports 2020 Financial Results, NOXXON Successfully Completes Patient Recruitment in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy, NOXXON Pharma: Data Safety Monitoring Board Confirms Safety and Validates Recruitment of Last Patients in Final High-Dose Cohort, NOXXON Enrolls First Patient in the High Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain, NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board, NOXXON Appoints Experienced Cancer Drug Developer Dr. Jose Saro as Chair of Scientific Advisory Board, NOXXON Announces Capital Increase of €6.4 Million by Private Placement to Further Develop Its Business, Dogecoin Isn't a Joke Anymore, Says FTX Founder, Max-Dohrn-Strasse 8-10 Actionnaires. Chart. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Terms and Conditions Privacy Center Disclosures Member User Agreement Corrections Cookies Accessibility. Forum. Regulatory News: © Copyright 2021 Morningstar, Inc. All rights reserved. Noxxon Pharma N.V. is listed on Euronext Growth Paris (ALNOX). He also served as Chairman of the Board of immuno-oncology company Rigontec GmbH until its acquisition by MSD in September 2017 and Board member of Serendex Pharmaceuticals A/S (Oslo Stock Exchange) until its acquisition by Savara Pharmaceuticals. Click here for more on how to use these ratings. Get NOXXON Pharma NV (ALNOX-FR:Euronext Paris) real-time stock quotes, news, price and financial information from CNBC. Free forex prices, toplists, indices and lots more. NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris : ALNOX), société biopharmaceutique développant principalement des traitements contre le cancer en ciblant le microenvironnement tumoral, annonce aujourd’hui avoir reçu, à la suite de discussions avec des investisseurs, des lettres d'intention et des engagements fermes pour un investissement à long terme … Name: NOXXON Pharma N.V. Ticker: ALNOX; Exchange: ENXTPA; Founded: 1997; Industry: Biotechnology; Sector: Pharmaceuticals & Biotech; Market Cap: €28.720m; Shares outstanding: 61.37m; Website: https://www.noxxon.com Consensus. fair value, and uncertainty rating. View the latest NOXXON Pharma AG (ALNOX) stock price, news, historical charts, analyst ratings and financial information from WSJ. is responsible for overseeing the methodology that supports the quantitative fair value. He served as executive chairman of Contera Pharma ApS until it was sold to Bukwang Pharma in November 2014. NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). SEE QUOTE. From Aug 2019 to Aug 2020. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. . For information Touch device users, explore by touch or with swipe gestures. NOXXON PHARMA NV E:ALNOXP - Turquoise is the European Multilateral Trading Facility (MTF) majority owned by London Stock Exchange Group in partnership with the user community, providing members a single connection to trade securities from 19 European and emerging markets as well as US stocks, IOB Depositary Receipts, ETFs and European Rights Issues Berlin, 10589 CURRENT PRICE. Germany, Deutsche Effecten- und Wechsel- Beteiligungsgesellschaft AG. All its product candidates are based on a new class of drug called Spiegelmers, which are identified and synthesized through a proprietary discovery platform which the Group believes offers specific advantages over other drug classes. Add to watchlist. All operational activities are conducted in Berlin. Based on the current price of €0.43 the target price of €1.00 shows a potential of 132.019% for Noxxon Pharma N.v. which would more than double the current price. The Company's main product is the Spiegelmer platform. ALNOX | Complete NOXXON Pharma AG stock news by MarketWatch. employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics Noxxon Pharma is a biotechnology company founded in 1997 in Berlin, Germany and is focused on improving cancer treatment by targeting the tumor microenvironment. NOXXON PHARMA Cours Action ALNOX, Cotation Bourse Euronext Paris - Boursorama.